Elevation Capital Expenditure Coverage Ratio from 2010 to 2024
| ELEV Stock | USD 4.02 0.05 1.23% |
Capital Expenditure Coverage Ratio | First Reported 2010-12-31 | Previous Quarter 894.59 | Current Value 466.88 | Quarterly Volatility 325.51898638 |
Check Elevation Oncology financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Elevation main balance sheet or income statement drivers, such as Depreciation And Amortization of 37 K, Interest Expense of 4.4 M or Selling General Administrative of 9.2 M, as well as many exotic indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 0.35. Elevation financial statements analysis is a perfect complement when working with Elevation Oncology Valuation or Volatility modules.
Elevation | Capital Expenditure Coverage Ratio |
Latest Elevation Oncology's Capital Expenditure Coverage Ratio Growth Pattern
Below is the plot of the Capital Expenditure Coverage Ratio of Elevation Oncology over the last few years. It is Elevation Oncology's Capital Expenditure Coverage Ratio historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Elevation Oncology's overall financial position and show how it may be relating to other accounts over time.
| Capital Expenditure Coverage Ratio | 10 Years Trend |
|
Capital Expenditure Coverage Ratio |
| Timeline |
Elevation Capital Expenditure Coverage Ratio Regression Statistics
| Arithmetic Mean | 350.32 | |
| Geometric Mean | 260.61 | |
| Coefficient Of Variation | 92.92 | |
| Mean Deviation | 259.76 | |
| Median | 173.21 | |
| Standard Deviation | 325.52 | |
| Sample Variance | 105,963 | |
| Range | 821 | |
| R-Value | 0.68 | |
| Mean Square Error | 62,015 | |
| R-Squared | 0.46 | |
| Significance | 0.01 | |
| Slope | 49.18 | |
| Total Sum of Squares | 1.5M |
Elevation Capital Expenditure Coverage Ratio History
About Elevation Oncology Financial Statements
There are typically three primary documents that fall into the category of financial statements. These documents include Elevation Oncology income statement, its balance sheet, and the statement of cash flows. Elevation Oncology investors use historical funamental indicators, such as Elevation Oncology's Capital Expenditure Coverage Ratio, to determine how well the company is positioned to perform in the future. Although Elevation Oncology investors may use each financial statement separately, they are all related. The changes in Elevation Oncology's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Elevation Oncology's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Elevation Oncology Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Elevation Oncology. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Capital Expenditure Coverage Ratio | 894.59 | 466.88 |
Pair Trading with Elevation Oncology
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Elevation Oncology position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Elevation Oncology will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Elevation Oncology could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Elevation Oncology when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Elevation Oncology - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Elevation Oncology to buy it.
The correlation of Elevation Oncology is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Elevation Oncology moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Elevation Oncology moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Elevation Oncology can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out the analysis of Elevation Oncology Correlation against competitors. For more information on how to buy Elevation Stock please use our How to Invest in Elevation Oncology guide.Note that the Elevation Oncology information on this page should be used as a complementary analysis to other Elevation Oncology's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.
Complementary Tools for Elevation Stock analysis
When running Elevation Oncology's price analysis, check to measure Elevation Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Elevation Oncology is operating at the current time. Most of Elevation Oncology's value examination focuses on studying past and present price action to predict the probability of Elevation Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Elevation Oncology's price. Additionally, you may evaluate how the addition of Elevation Oncology to your portfolios can decrease your overall portfolio volatility.
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas |
Is Elevation Oncology's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Elevation Oncology. If investors know Elevation will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Elevation Oncology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.85) | Return On Assets (0.26) | Return On Equity (0.72) |
The market value of Elevation Oncology is measured differently than its book value, which is the value of Elevation that is recorded on the company's balance sheet. Investors also form their own opinion of Elevation Oncology's value that differs from its market value or its book value, called intrinsic value, which is Elevation Oncology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Elevation Oncology's market value can be influenced by many factors that don't directly affect Elevation Oncology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Elevation Oncology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Elevation Oncology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Elevation Oncology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.